` CLYM (Climb Bio Inc) vs S&P 500 Comparison - Alpha Spread

CLYM
vs
S&P 500

Over the past 12 months, CLYM has significantly outperformed S&P 500, delivering a return of +125% compared to the S&P 500's +14% growth.

Stocks Performance
CLYM vs S&P 500

Loading
CLYM
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CLYM vs S&P 500

Loading
CLYM
S&P 500
Difference
www.alphaspread.com

Performance By Year
CLYM vs S&P 500

Loading
CLYM
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Climb Bio Inc vs Peers

S&P 500
CLYM
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Climb Bio Inc
Glance View

Market Cap
298.6m USD
Industry
Biotechnology

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.

CLYM Intrinsic Value
Not Available
Back to Top